|March 28, 2014|
|07:40 EDT||ARIA, JAZZ||ARIAD volatility is expected to move on acquisition rumors reports |
ARIAD (ARIA) volatility is expected to move on rumors suggest that Jazz Pharmaceuticals (JAZZ) is willing to pay $20-plus per share to acquire ARIAD, Daily Mail says. Overall option implied volatility of 81 is below its 26-week average of 100 according to Track Data, suggesting decreasing price movement.
News For ARIA;JAZZ From The Last 14 Days
|March 30, 2015|
|07:24 EDT||JAZZ||Stifel to hold a bus tour|
BioTrek: 2015 West Coast Healthcare Therapeutics Bus Tour travels throughout San Francisco on March 30-April 1.
|March 27, 2015|
|06:17 EDT||JAZZ||Jazz Pharmaceuticals assumed with a Buy at Citigroup|
Price target lowered to $195 from $202.
|March 26, 2015|
|07:30 EDT||JAZZ||Deutsche Bank to hold a conference|
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
|March 25, 2015|
|09:29 EDT||ARIA||ARIAD reports dismissal of class action suit in federal district court|
ARIAD Pharmaceuticals announced that the United States District Court for the District of Massachusetts dismissed the shareholder class action lawsuit filed in late 2013 against the company and certain of its officers, directors and underwriters in connection with the events leading up to the temporary suspension of the marketing and commercial distribution of Iclusig on October 31, 2013, and subsequent re-launch in January 2014 based on revised U.S. prescribing information and a risk evaluation and mitigation strategy. The suit alleged that certain of the company defendants made a series of false and misleading statements regarding the safety, efficacy and commercial prospects of Iclusig. The Court granted the company’s motion to dismiss the lawsuit, concluding that the plaintiffs failed to establish that any such statements violated the company’s disclosure obligations as asserted in the complaint. “We are pleased that for the second time in as many weeks, the Court has granted our motion to dismiss what we believed from the outset was another meritless lawsuit,” said Harvey J. Berger, M.D., chairman and CEO. “Our corporate values of integrity and mutual respect are always at the forefront as we continue to focus on executing our plan for sustained revenue growth and operational excellence, leading to anticipated profitability in 2018.”
|March 24, 2015|
|09:22 EDT||ARIA||On The Fly: Pre-market Movers |
Subscribe for More Information
|07:37 EDT||ARIA||ARIAD announces approval of Iclusig in Israel|
ARIAD Pharmaceuticals and Medison Pharma announced that the Israeli Ministry of Health has granted regulatory approval for Iclusig, ponatinib, in Israel for adult patients with: Chronic phase, accelerated phase, or blast phase chronic myeloid leukaemia who are resistant to dasatinib or nilotinib, who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation Philadelphia chromosome-positive acute lymphoblastic leukaemia who are resistant to dasatinib, who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate, or who have the T315I mutation. ARIAD submitted its application for Iclusig to the Israeli Ministry of Health in June 2014. Commercial launch of Iclusig is expected to occur in Q2.
|March 18, 2015|
|13:05 EDT||JAZZ||Jazz Pharmaceuticals management to meet with Piper Jaffray|
Subscribe for More Information